1080TiP An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT) - Galvao, V.; Palomero, J.; Creus-Gonzalez, I.; Lostes Bardaji, M.J.; Lozano-Rabella, M.; Garcia-Garijo, A.; Yuste, A.; Rodriguez, L.; Villalobos Alberú, X.; Rotxes, M.; Vieito Villar, M.; Saavedra Santa Gadea, O.; et al. (Annals of Oncology, 2023)